QuarterlyIQ Insights · BIIB
Earnings
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Next earnings
Average absolute move on past earnings days.
Annualized — recent baseline volatility.
Guidance track record
Of the last 4 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings events
Earnings prints and pre-announcements detected in the SEC filing stream.
- 2026-04-29earnings beat
Results of Operations and Financial Condition. On April 29, 2026, Biogen Inc. issued a press release announcing its results of operations and financial condition for the first quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The press release is being furnished pursuant to
positive73 - 2026-04-06earnings beat
Results of Operations and Financial Condition Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the first quarter of 2026 will include acquired in-process research and development, upfront and milestone expense of approximately $34 million on a pre-tax basis. The estimated charge is expected to impact GAAP and non-GAAP net income per diluted share for the first quarter of 2026 by approximately $0.19 per share. Acquired in-process research and development, upfront and milesto…
positive73 - 2026-02-06earnings beat
Results of Operations and Financial Condition. On February 6, 2026, Biogen Inc. issued a press release announcing its results of operations and financial condition for the fourth quarter and year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The press release is being furnished pursuant to
positive73 - 2026-01-13earnings beat
Results of Operations and Financial Condition Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the fourth quarter of 2025 will include acquired in-process research and development, upfront and milestone expense of approximately $222 million on a pre-tax basis. The estimated charge is expected to impact GAAP and non-GAAP net income per diluted share for the fourth quarter 2025 by approximately $1.26 per share. During the first quarter of 2025 we began presenting acquired in-…
positive73 - 2025-10-30earnings beat
Results of Operations and Financial Condition. On October 30, 2025, Biogen Inc. issued a press release announcing its results of operations and financial condition for the third quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The press release is being furnished pursuant to
positive73 - 2025-10-14earnings beat
Results of Operations and Financial Condition Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the third quarter of 2025 will include acquired in-process research and development, upfront and milestone expense of approximately $2 million on a pre-tax basis. The estimated charge is expected to impact GAAP and non-GAAP net income per diluted share for the third quarter 2025 by approximately ($0.01) per share. During the first quarter of 2025 we began presenting acquired in-pr…
positive73 - 2025-07-31earnings beat
Results of Operations and Financial Condition. On July 31, 2025, Biogen Inc. issued a press release announcing its results of operations and financial condition for the second quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The press release is being furnished pursuant to
positive73 - 2025-07-07earnings beat
Results of Operations and Financial Condition Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the second quarter of 2025 will include acquired in-process research and development, upfront and milestone expense of approximately $46 million on a pre-tax basis. The estimated charge is expected to impact GAAP and non-GAAP net income per diluted share for the second quarter 2025 by approximately ($0.26) per share. During the first quarter of 2025 we began presenting acquired in…
positive73 - 2025-05-01earnings inline
Results of Operations and Financial Condition. On May 1, 2025, Biogen Inc. issued a press release announcing its results of operations and financial condition for the first quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The press release is being furnished pursuant to
neutral67 - 2025-02-12earnings inline
Results of Operations and Financial Condition. On February 12, 2025, Biogen Inc. issued a press release announcing its results of operations and financial condition for the fourth quarter and year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The press release is being furnished pursuant to
neutral67 - 2024-10-30earnings inline
Results of Operations and Financial Condition. On October 30, 2024, Biogen Inc. issued a press release announcing its results of operations and financial condition for the third quarter ended September 30, 2024. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The press release is being furnished pursuant to
neutral67 - 2024-08-01earnings beat
Results of Operations and Financial Condition. On August 1, 2024, Biogen Inc. issued a press release announcing its results of operations and financial condition for the second quarter ended June 30, 2024. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The press release is being furnished pursuant to
positive73 - 2024-04-24earnings inline
Results of Operations and Financial Condition. On April 24, 2024, Biogen Inc. issued a press release announcing its results of operations and financial condition for the first quarter ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The press release is being furnished pursuant to
neutral67 - 2024-02-13earnings inline
Results of Operations and Financial Condition. On February 13, 2024, Biogen Inc. issued a press release announcing its results of operations and financial condition for the fourth quarter and year ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The press release is being furnished pursuant to
neutral67 - 2023-11-08earnings inline
Results of Operations and Financial Condition. On November 8, 2023, Biogen Inc. issued a press release announcing its results of operations and financial condition for the third quarter ended September 30, 2023. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The press release is being furnished pursuant to
neutral67 - 2023-07-25earnings inline
Results of Operations and Financial Condition. On July 25, 2023, Biogen Inc. issued a press release announcing its results of operations and financial condition for the second quarter ended June 30, 2023. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The press release is being furnished pursuant to
neutral67
EPS / revenue actuals and consensus per quarter (8-quarter history) need a mart view over AlphaVantage EARNINGS + EARNINGS_ESTIMATES — the backend ingest exists but isn't exposed to the frontend yet. Once that lands we can show beat/miss, surprise size, and forward consensus on this tab.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.